International Law Enforcement Action Against Fake Medicines
Law enforcement authorities from Austria, Belgium, Cyprus, France, Hungary, Slovakia, Spain and the United Kingdom, supported by Europol and Eurojust, today contributed to simultaneous...
UK Government to provide additional £160m to Cancer Drugs Fund
The UK Government is set to add an additional £160m to the Cancer Drugs Fund, in order to improve treatment for patients. The funding...
Roche to acquire InterMune for $8.3bn
Swiss drugmaker Roche has signed a definitive merger agreement to acquire InterMune for around $8.3bn. As part of the all-cash transaction, Roche has offered...
EISAI Files Lenvatinib in Europe for People With Radioiodine-Refractory Thyroid Cancer
FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. MEDIA
EMA accepts accelerated review for orphan therapy in hard-to-treat thyroid cancer
Eisai announces today that it has filed...
UCB Biologics Pilot Plant, Braine-l’Alleud
Brussels-based biopharmaceutical company Union Chimique Belge (UCB) broke ground for a new biotechnology pilot facility in Belgium in June 2010. The facility, located at...
Vivalis R&D Facility
Vivalis opened a new R&D facility in Saint-Herblain, Nantes, France on 28 June 2010. The facility, located adjacent to its existing bio-production facility, has...
Roche Pharmaceutical Manufacturing Plant
Roche Mustahzarlari has completed the construction of their pharmaceutical facility at Gebze, close to Istanbul, Turkey. The new drugs manufacturing facility will make solid...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...